Objective: The objective of this report is to assess the presence and viral load of JC polyomavirus (JCV) DNA in cerebrospinal fluid (CSF) and plasma from neuropsychiatric systemic lupus erythematosus (NPSLE) patients in comparison to controls and to investigate if different types of immunosuppressive treatments were correlated to detection and viral load of JCV DNA in SLE. Background: Reactivation of a latent JCV infection with subsequent development of the fatal disease progressive multifocal leukoencephalopathy (PML) has become an increasing problem in patients with autoimmune diseases treated with newer immunosuppressants. Accumulating data point out that SLE patients are at particular risk for PML compared to patients with other rheumatic diseases. Methods: CSF samples (n ¼ 69) and plasma samples (n ¼ 51) from 71 SLE patients and 58 controls (53 CSF samples and 50 plasma samples) with other non-inflammatory neurological disease (OND) were analyzed for JCV DNA with a quantitative PCR method. Results: All CSF and plasma samples from NPSLE patients and controls were negative for JCV DNA. Conclusion: JCV DNA was absent in CSF and plasma in NPSLE patients and controls and consequently we were not able to identify any correlation between the occurrence of JCV DNA and type of immunosuppressive medication. Lupus (2013) 22, 307-311.
Introduction
Progressive multifocal leukoencephalopathy (PML) is a rare, serious demyelinating disease of the central nervous system (CNS) caused by the John Cunningham virus (JCV). Primary infection with JCV is usually asymptomatic, occurs in childhood and is followed by lifelong viral persistence. The kidneys, bone marrow, and lymphoid tissue have been demonstrated as common reservoirs for JCV latency. 1 Some studies have also shown that the healthy brain can harbor JCV. 2 PML occurs as a consequence of reactivation of JCV whereby the virus escapes latency, enters the CNS and causes a lytic infection of oligodendrocytes leading to demyelination. Reactivation of JCV is most commonly associated with conditions of immunosuppression but there are reports of PML developing in immunocompetent individuals. 3 The majority of PML cases have been described in acquired immune deficiency syndrome (AIDS) patients, followed by immunosuppressed people, including patients with malignancies, transplant recipients and to a lesser extent autoimmune patients treated with immunomodulatory medication. 1 The incidence of PML in autoimmune diseases, including rheumatic diseases, has recently increased as a consequence of an increased use of new, more potent immunosuppressive drugs such as biologics (rituximab, natalizumab, infliximab and efalizumab) and other potent immunomodulatory medication like mycophenolate mofetil. 4 Recent data emphasize that patients with systemic lupus erythematosus (SLE) confer a higher risk for PML and the risk is increased even in SLE patients with a minimum of immunomodulatory treatment. [5] [6] [7] The underlying mechanisms for this observation are unresolved and poorly investigated. The clinical and radiological presentation of neuropsychiatric systemic lupus erythematosus (NPSLE) is extremely heterogeneous 8 and can thus be difficult to distinguish from classical signs and symptoms of PML. Due to the similarities between PML and NPSLE, the PML diagnosis is likely to be delayed in NPSLE patients, and PML might be underdiagnosed in this patient group. 7, 9 There is a lack of clinical and laboratory predictors for PML and there is a great need for identification of factors triggering PML development.
The aim of this study was to analyze whether JCV DNA can be detected in plasma or cerebrospinal fluid (CSF) in a large group of patients with NPSLE treated with different types and amounts of immunomodulatory medication. JCV DNA was analyzed with a quantitative polymerase chain reaction (PCR) method in CSF (n ¼ 69) and plasma (n ¼ 51) from 71 NPSLE patients and 58 controls with other non-inflammatory neurological disease (OND), CSF (n ¼ 53), plasma (n ¼ 50).
Materials and methods
Subjects and sample preparation SLE patients suffering previous clinical neurological symptoms when included in a cross-sectional cohort study at the Department of Rheumatology, Karolinska University Hospital, were asked to participate. All patients fulfilled at least four of the American College of Rheumatology (ACR) classification criteria for SLE. 8 Seventy-one consenting patients were included chronologically, five of 71 males, median age 49 years (interquartile range (IQR) 21-77 years), all of Caucasian origin. The patients underwent a structured clinical investigation by a rheumatologist and neurologist and information was collected by a structured interview. The presence of ongoing/prior neuropsychiatric manifestations was classified according to the ACR nomenclature of NPSLE syndromes by 19 distinct case definitions, 8 as shown in Figure 1 . Ongoing and prior immunomodulatory treatment was documented. The controls included 58 patients with other non-inflammatory neurological disease (OND) (16/58 males, median age 39 years, IQR 31-43 years) from whom samples were obtained from our in-house biobank at the Department of Neurology, Karolinska University Hospital. All control patients were treatment naı¨ve; their diagnoses are listed in the Appendix. The study was approved by the regional ethical committee, and written informed consent was obtained from all study participants.
JCV PCR analysis
The patients underwent lumbar puncture and collection and processing of CSF and plasma samples were performed as previously described. 10 Total DNA was extracted from 200 ml of plasma or CSF using M48 Blood and Tissue Midikit (Qiagen, Hilden, Germany) in combination with the M48 Biorobot (Qiagen, Hilden, Germany) according to the manufacturer's protocol. DNA obtained from the plasma samples was eluated in a volume equal to the starting volume, while DNA obtained from the CSF samples was eluated in a final volume of 50 ml. Quantification of JCV DNA was performed by real time PCR (qPCR) as previously described. 11 The specific JCV primers and probe were designed to amplify a part of the VP 2 region (forward primer 5 0 CTGAACC AAAAGCTACATAGTAAGTAATGT-3 0 , reverse primer 5 0 CTAGTCCCCCAAAAGTGGAA-3, probe 5 0 FAM-AGGTTCATGGGTGCCGC-3 0 MGB). The detection limit for JCV DNA in plasma was 200 copies/ml, and corresponding limit for CSF was 50 copies/ml.
Results
Seventy-one NPSLE patients and 58 OND controls were included in the study; demographic data of the 9) anxiety disorder (n ¼ 4), 10) cognitive disorder (n ¼ 26), 11) mood disorder (n ¼ 11), 12) psychosis (n ¼ 2); peripheral nervous system: 13) Guillan-Barre´syndrome (n ¼ 0), 14) autonomic neuropathy (n ¼ 0), 15) mono neuropathy (n ¼ 2), 16) myasthenia gravis (n ¼ 0) 17) cranial neuropathy (n ¼ 8), 18) plexopathy (n ¼ 2), and 19) poly-neuropathy (n ¼ 7). Multiple NPSLE events were present in the majority of 71 SLE patients. ACR: American College of Rheumatology. patients are described in Table 1 . Sixty-three of the NPSLE patients had ongoing treatment with immunomodulatory medication at the time of sampling ( Table 2) . Five NPSLE patients were treatment naı¨ve and eight of the patients had no immunomodulatory treatment at the time of sampling but had been treated with such medication prior to sampling. We analyzed CSF (n ¼ 69) and plasma (n ¼ 51) from 71 NPSLE patients and CSF (n ¼ 53) and plasma (n ¼ 50) from 58 controls. Paired CSF and plasma samples were obtained from 49 of the NPSLE patients and 44 of the control patients. All CSF and plasma samples from NPSLE patients as well as control patients were negative for JCV DNA. All NPSLE patients have been followed clinically, after sampling, for a mean of 5.4 years (range three to eight years) and none of them have developed clinical signs of PML. Six SLE patients died during the follow-up time; causes of death were cerebral vasculitis and pneumonia, CNS demyelination and pneumonia, cortical dementia, depression and cognitive impairment, ischemic heart disease and cerebrovascular disease.
Discussion
In this study, we did not detect JCV DNA in CSF or plasma in a large group of patients with NPSLE, of whom the majority had been exposed to varying degrees of immunosuppressive treatment. Five patients had been treated with the biologic drug rituxiumab and six patients had been treated with mycophenolate mofetil, which both have been associated with an increased risk of PML. 12 Absence of JCV DNA in CSF and plasma was also observed in our control group consisting of patients with OND.
We have previously analyzed JCV DNA in CSF and plasma in multiple sclerosis (MS) and control patients, including a few SLE patients. In this study JCV DNA was detected in plasma, but not CSF, in two of the SLE patients. 10 These patients have been followed clinically for more than five years without any signs of PML development. The observation of JCV DNA in the SLE patients encouraged us to perform the present study, and we hypothesized that different types and duration of immunosuppressive medication could be associated with reactivation of JCV and detection of JCV in the systemic circulation or in CSF. Such association was, however, not found since all of the samples were negative for JCV DNA.
There are several reports of PML occurring in SLE, both in association with newer biologic immunosuppressants 12 but also in patients treated with conventional disease-modifying agents. 7, 9 The incidence and prevalence of PML in SLE is not known but substantial data indicate an increased risk for PML compared to other rheumatic diseases; Calabrese and Molloy have reviewed the literature on case reports of PML occurring in patients with rheumatic diseases and identified 50 PML cases, of which 64% were patients diagnosed with SLE. 3, 13 The same authors performed a study on the national estimate on the frequency of PML in SLE and other rheumatic diseases based on United States (US) hospital discharges that demonstrated a comparatively high frequency of four PML cases per 100,000 discharges of SLE while the corresponding number was 0.4 in rheumatoid arthritis (RA) and two in patients with other connective-tissue diseases. 5 In addition Calabrese and Molloy recently published data on PML reported in association with autoimmune rheumatic diseases in the US Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) database. 14 In this study 34 cases of PML were confirmed, of which 17 occurred in patients with SLE. 14 In another study from the US, based on data obtained from a large health insurer, an incidence rate of PML in SLE patients of 2.4 per 100,000 person-years was observed. 15 From Sweden, a retrospective study on the incidence of PML in SLE, during a period of 25 years, demonstrated a minimum risk for PML as three of 200, which corresponds to one PML case per 800 patient-years. 7 Branda˜o et al. followed SLE patients in their immunology outpatient clinic and reported on two cases of PML out of 608 SLE patients. 21 The mechanisms involved in the pathogenesis of JCV reactivation and development of PML are largely unknown. JCV exists in two genetic forms differing in their noncoding control region (NCCR). The archetypal form is the genetic variant of the virus associated with latency. During reactivation, the virus undergoes genetic rearrangements in the NCCR and transforms into the neurotrophic PML strain. 16 The site and mechanism of JCV transformation are not clarified. The generally accepted hypothesis is that PML is caused by reactivation of JCV at times of immunosuppression whereby the virus migrates to the brain and causes a lytic destruction of the glial cells and hence PML. 16 However, since some studies also have demonstrated JCV latency within the CNS, it has been suggested that PML may occur as a consequence of reactivation of a latent JCV infection in the brain. 2 Interestingly, Bayliss et al. demonstrated that latent JCV DNA in the brain is more common in immunosuppressed human immunodeficiency virus (HIV)/AIDS patients compared to immunocompetent patients. 17 When reviewing the literature we observed only one previous study investigating the presence of JCV DNA in peripheral blood samples from SLE patients, which in accordance with the present study, reported negative detection of JCV DNA. 18 By contrast, there are several researchers who have studied a possible correlation between induction of JCV DNA in the blood and treatment with the biological drug natalizumab in patients with MS. Sadiq et al. observed the appearance of JCV DNA in one of 93 plasma samples and in two of 93 CSF samples after starting treatment with natalizumab, although none of these patients developed PML. 19 Rudick et al. analyzed a large number of blood samples from natalizumab-treated MS patients, including five patients who developed PML, and they observed that JCV DNA was present in a very low number of patients of whom none developed PML. In addition, in the five PML cases, JCV DNA was detected in the blood only after the onset of PML-related symptoms. 20 In conclusion, these studies indicate that analysis of JCV DNA in blood as a tool for risk stratification of PML is unlikely to identify patients with higher risk.
The mechanisms causing SLE patients to be predisposed to PML are poorly explained but the absence of a clear association with immunosuppressive treatments indicates that a disease-related immunological dysfunction might play an important role. The increased risk may also be related to host factors possibly found only in certain subgroups of SLE. It is known that conditions associated with cellular immunity dysfunctions increase the risk for JCV reactivation. 1 It has been suggested that in particular T CD4 þ lymphopenia may be important in the pathogenesis of PML in SLE. 21 Branda˜o et al. described two SLE patients who developed PML who had both been treated only with conventional immunosuppressants but had a profound T CD4 þ lymphopenia. 21 The importance of the present study is the demonstration that occurrence of JCV DNA is not common in blood and CSF among patients with NPSLE with different immunomodulatory treatments. Since the use of newer, more potent immunosuppressive treatments in SLE and other autoimmune diseases is associated with an increased risk of PML, it complicates decision making regarding its usage in patients with less malignant disease stages. It is of great importance to characterize the mechanisms in immunosuppressive conditions leading to reactivation of JCV and to identify risk predictors for PML, which can be implicated when planning individual treatment. PML seems to develop almost always as a recrudescence of a latent infection, and analysis of JCV IgG antibodies in serum is useful in order to find out whether the patient at all has been infected with JCV. 4 Uninfected patients should repeatedly be tested for JCV seroconversion during immunosuppressive treatment. Clinicians ought to have a high level of suspicion for PML in SLE. Diagnostic work-up, including brain magnetic resonance imaging (MRI) and JCV DNA PCR analysis in CSF, should be considered, without delay, in SLE patients presenting with unexplained progressive neurological signs or symptoms.
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